Cargando…

Syndecans as Modulators and Potential Pharmacological Targets in Cancer Progression

Extracellular matrix (ECM) components form a dynamic network of key importance for cell function and properties. Key macromolecules in this interplay are syndecans (SDCs), a family of transmembrane heparan sulfate proteoglycans (HSPGs). Specifically, heparan sulfate (HS) chains with their different...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barbouri, Despoina, Afratis, Nikolaos, Gialeli, Chrisostomi, Vynios, Demitrios H., Theocharis, Achilleas D., Karamanos, Nikos K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910246/ https://www.ncbi.nlm.nih.gov/pubmed/24551591 http://dx.doi.org/10.3389/fonc.2014.00004

Ejemplares similares

Preparation and Toxicological Assessment of Functionalized Carbon Nanotube-Polymer Hybrids
por: Koromilas, Nikos D., et al.
Publicado: (2014)

Expression of Syndecan-4 and Correlation with Metastatic Potential in Testicular Germ Cell Tumours
por: Labropoulou, Vassiliki T., et al.
Publicado: (2013)

IGF-IR cooperates with ERα to inhibit breast cancer cell aggressiveness by regulating the expression and localisation of ECM molecules
por: Afratis, Nikolaos A., et al.
Publicado: (2017)

Serglycin: At the Crossroad of Inflammation and Malignancy
por: Korpetinou, Angeliki, et al.
Publicado: (2014)

Metabolism of Cartilage Proteoglycans in Health and Disease
por: Vynios, Demitrios H.
Publicado: (2014)

ADAMTS Expression in Colorectal Cancer
por: Filou, Serafula, et al.
Publicado: (2015)

Editorial: Molecules of the extracellular matrix as cancer targets
por: Karamanos, Nikos K., et al.
Publicado: (2022)

Complexity of matrix phenotypes
por: Iozzo, Renato V., et al.
Publicado: (2020)

Involvement of hyaluronidases in colorectal cancer
por: Bouga, Helen, et al.
Publicado: (2010)

Syndecans and Their Synstatins: Targeting an Organizer of Receptor Tyrosine Kinase Signaling at the Cell-Matrix Interface
por: Rapraeger, Alan C.
Publicado: (2021)

Serglycin activates pro-tumorigenic signaling and controls glioblastoma cell stemness, differentiation and invasive potential
por: Manou, Dimitra, et al.
Publicado: (2020)

Enhancement of mesenchymal stem cells’ chondrogenic potential by type II collagen-based bioscaffolds
por: Piperigkou, Zoi, et al.
Publicado: (2023)

Lumican Inhibits In Vivo Melanoma Metastasis by Altering Matrix-Effectors and Invadopodia Markers
por: Karamanou, Konstantina, et al.
Publicado: (2021)

Evaluation of the Diagnostic and Prognostic Value of Syndecan-1 in Acute Leukemia Patients
por: Alghandour, Reham, et al.
Publicado: (2020)

Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia
por: Lu, Rui, et al.
Publicado: (2017)

FACE Analysis as a Fast and Reliable Methodology to Monitor the Sulfation and Total Amount of Chondroitin Sulfate in Biological Samples of Clinical Importance
por: Karousou, Evgenia, et al.
Publicado: (2014)

The Role of Syndecan-1 in Cellular Signaling and its Effects on Heparan Sulfate Biosynthesis in Mesenchymal Tumors
por: Szatmári, Tünde, et al.
Publicado: (2013)

Increased Expression of Serglycin in Specific Carcinomas and Aggressive Cancer Cell Lines
por: Korpetinou, Angeliki, et al.
Publicado: (2015)

Lumican effectively regulates the estrogen receptors-associated functional properties of breast cancer cells, expression of matrix effectors and epithelial-to-mesenchymal transition
por: Karamanou, Konstantina, et al.
Publicado: (2017)

Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients
por: Muendlein, Axel, et al.
Publicado: (2022)

Interplay Between Chemotherapy-Activated Cancer Associated Fibroblasts and Cancer Initiating Cells Expressing CD44v6 Promotes Colon Cancer Resistance
por: Ghatak, Shibnath, et al.
Publicado: (2022)

Chemotherapy induces feedback up-regulation of CD44v6 in colorectal cancer initiating cells through β-catenin/MDR1 signaling to sustain chemoresistance
por: Ghatak, Shibnath, et al.
Publicado: (2022)

Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas
por: Skandalis, Spyros S, et al.
Publicado: (2011)

The chondroitin/dermatan sulfate synthesizing and modifying enzymes in laryngeal cancer: Expressional and epigenetic studies
por: Kalathas, Dimitrios, et al.
Publicado: (2010)

ESR2 Drives Mesenchymal-to-Epithelial Transition in Triple-Negative Breast Cancer and Tumorigenesis In Vivo
por: Piperigkou, Zoi, et al.
Publicado: (2022)

Neuroendocrine Tumors Show Altered Expression of Chondroitin Sulfate, Glypican 1, Glypican 5, and Syndecan 2 Depending on Their Differentiation Grade
por: García-Suárez, Olivia, et al.
Publicado: (2014)

Syndecan-1-Dependent Regulation of Heparanase Affects Invasiveness, Stem Cell Properties, and Therapeutic Resistance of Caco2 Colon Cancer Cells
por: Katakam, Sampath Kumar, et al.
Publicado: (2020)

Differential Impact of Membrane-Bound and Soluble Forms of the Prognostic Marker Syndecan-1 on the Invasiveness, Migration, Apoptosis, and Proliferation of Cervical Cancer Cells
por: Hilgers, Katharina, et al.
Publicado: (2022)

Ionizing radiation-mediated premature senescence and paracrine interactions with cancer cells enhance the expression of syndecan 1 in human breast stromal fibroblasts: the role of TGF-β
por: Liakou, Eleni, et al.
Publicado: (2016)

Pharmacological Modulation of Anti-Tumor Immunity Induced by Oncolytic Viruses
por: Forbes, Nicole E., et al.
Publicado: (2014)

Pharmacological targets for the induction of ferroptosis: Focus on Neuroblastoma and Glioblastoma
por: Ferrada, Luciano, et al.
Publicado: (2022)

Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy
por: Giacomini, Isabella, et al.
Publicado: (2021)

Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression
por: Beauvais, DeannaLee M., et al.
Publicado: (2022)

Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets
por: Petrusca, Daniela N., et al.
Publicado: (2022)

Role of Syndecans in Ovarian Cancer: New Diagnostic and Prognostic Biomarkers and Potential Therapeutic Targets
por: Oto, Julia, et al.
Publicado: (2023)

Syndecan-3 and syndecan-4 are enriched in Schwann cell perinodal processes
por: Goutebroze, Laurence, et al.
Publicado: (2003)

Modulation of Syndecan-1 Shedding after Hemorrhagic Shock and Resuscitation
por: Haywood-Watson, Ricky J., et al.
Publicado: (2011)

An Integrated Network, RNA Sequencing, and Experiment Pharmacology Approach Reveals the Active Component, Potential Target, and Mechanism of Gelsemium elegans in the Treatment of Colorectal Cancer
por: Wang, Lin, et al.
Publicado: (2020)

Peroxisome Proliferator-Activated Receptor-γ Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer
por: Giaginis, Costas, et al.
Publicado: (2008)

Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors
por: Madkour, Moustafa M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6mqm9nuhsh2q46735p7it0buv7